The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
A roundup of developments from Dominican Republic and Germany, (Fresenius Kabi), India (Aurobindo), and the US (FDA).
Dominican Republic
Fresenius Kabi Expands Apheresis Sets Production Site in Dominican Republic
Fresenius Kabi, a Bad Homburg,...
Merck & Co. plans to spin off products from its Women’s Health, Legacy Brands, and Biosimilars businesses to form a new, yet-to-be-named, independent, publicly traded company (NewCo) while retaining higher growth products in Merck. The spinoff...
Sandoz, the generics and biosimilars arm of Novartis, has completed its acquisition of the Japanese business of Aspen Global Inc. (AGI), a wholly owned subsidiary of the specialty and branded pharmaceutical company, Aspen Pharmacare, in a deal...
As part of an investigation of potential nitrosamine impurities in metformin, the active pharmaceutical ingredient (API) in diabetes medications, the US Food and Drug Administration (FDA) reported that the levels of nitrosodimethylamine (NDMA), a...
The US Food and Drug Administration (FDA) has outlined its actions to advance development of coronavirus (2019-nCoV) medical countermeasures for the outbreak in Wuhan, China. This includes collaboration with interagency partners, product...
Johnson & Johnson (J&J) has announced that it is launching a multi-pronged response to the coronavirus (2019-nCoV or Wuhan coronavirus) outbreak, which includes initiating development of a vaccine candidate against 2019-nCoV and broadly...
A roundup of developments and latest news from China (WuXi Biologics), India (Biocon), UK (AstraZeneca), US (Krystal Biotech).
China
WuXi Biologics Provides Update on Activities Relating to Coronavirus in China
WuXi Biologics, a contract...
Sanofi has completed its $2.5-billion acquisition of Synthorx, a clinical-stage biotechnology company developing treatments for cancer and autoimmune disorders.
With the completion of the deal, Sanofi will gain access to Synthorx’s lead...
Allergan has opened an EUR 160 million ($176 million) biologics facility at its Westport Campus in County Mayo, Ireland. The new facility will act as a global hub for Allergan’s flagship products, including Botox (onabotulinumtoxinA), one of its...
Pfizer has launched its Vaccines Division’s Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific...
Merck KGaA is investing EUR 250 million ($275 million) over the 2019-2022 period in a new Biotech Development Center for biopharmaceutical development and manufacturing for new biological entities in clinical studies in Corsier-sur-Vevey,...
As part of the ongoing regulatory approval process for AbbVie’s pending $63-billion acquisition of Allergan, Allergan has agreed to divest three drugs: one investigational drug to AstraZeneca and two commercial products to Nestlé. AbbVie has also...
AstraZeneca plans to invest $1 billion under a strategy to achieve zero-carbon emissions from its global operations by 2025 and to ensure its entire value chain is carbon-negative by 2030.
Launched this week at the World Economic Forum (WEF)...
Piramal has agreed to sell its healthcare data and analytics unit, Decision Resources Group (DRG), to Clarivate Analytics for $950 million (includes $900 million on closing and $50 million to be received at the end of 12 months from the date of...
Merck & Co. has completed its previously announced $2.7-billion acquisition of ArQule, a biopharmaceutical company focused on the discovery and development of kinase inhibitors for treating cancer and other diseases. With the completion of the...
